Onconetix, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONCO research report →
Price Chart
About the company
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication.
- CEO
- David Allan White
- IPO
- 2022
- Employees
- 2
- HQ
- Cincinnati, OH, US
Get TickerSpark's AI analysis on ONCO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.04M
- P/E
- -0.02
- PEG
- 0.00
- P/S
- 2.42
- P/B
- -0.07
- EV/EBITDA
- 0.56
- Div Yield
- 0.00%
- Gross Margin
- 73.81%
- Op Margin
- -1687.48%
- Net Margin
- -7423.86%
- ROE
- -557.89%
- ROIC
- -64.66%
Latest fiscal year · YoY change
- Revenue
- $815.37K-67.7%
- Gross Profit
- $632.91K-40.0%
- Op Income
- $-6,344,856
- Net Income
- $-14,032,342+76.1%
- EPS
- $-47.30+99.1%
- OCF Growth
- +7.8%
- FCF Growth
- +8.0%
- 52W High
- $1610.00
- 52W Low
- $2.76
- 50D MA
- $5.79
- 200D MA
- $85.67
- Beta
- 2.62
- RSI (14)
- 38
- Avg Volume
- 412.58K
No earnings-call transcripts are available for ONCO yet.
- Free Float
- 32.0%
- Shares Outstanding
- 358.43K
- Float Shares
- 114.64K
of shares held by institutions
5 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 21, 26 | HRT FINANCIAL LP | sell | 49,710 |
| Apr 17, 26 | HRT FINANCIAL LP | buy | 34,636 |
| Apr 16, 26 | HRT FINANCIAL LP | sell | 53,867 |
| Apr 20, 26 | HRT FINANCIAL LP | sell | 94,462 |
| Apr 15, 26 | HRT FINANCIAL LP | buy | 92,554 |
| Apr 14, 26 | HRT FINANCIAL LP | buy | 74,350 |
| Apr 14, 26 | HRT FINANCIAL LP | other | 0 |
| Mar 18, 26 | White David Allan | other | 0 |
| Mar 19, 26 | DORF SAMMY | other | 0 |
| Dec 5, 25 | Romano Sarah | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ONCO coverage
Recent articles, reports, and earnings notes.
No research on ONCO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ONCO report →Celularity (NASDAQ:CELU) and Onconetix (NASDAQ:ONCO) Financial Contrast
defenseworld.net · Nov 12
Realbotix Provides Update on Nasdaq Listing Timeline
businesswire.com · Nov 9
Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement
globenewswire.com · Oct 27
Onconetix Announces Reverse Stock Split
globenewswire.com · Oct 26
Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition
globenewswire.com · Oct 23
Realbotix Announces Additional Draw under Bridge Loan from Onconetix
businesswire.com · Oct 23
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Onconetix (NASDAQ:ONCO) Critical Comparison
defenseworld.net · Oct 10
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
globenewswire.com · Sep 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.